April 25th 2024
In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link between human papillomavirus infection and head and neck cancers.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Jean Kozempel to Receive 2017 Oncology Section President's Award
February 27th 2018The American Physical Therapy Association has selected Jean Kozempel, PT, DPT, MS, as the recipient of the 2017 Oncology Section President’s Award. This award honors physical therapists who are proving themselves to be pioneers in the oncology field.
Read More
Activity Seen With Tipifarnib in HRAS-Mutant HNSCC in Proof-of-Concept Study
December 27th 2017Tipifarnib demonstrated encouraging antitumor activity among patients with <em>HRAS</em>-mutant head and neck squamous cell carcinoma (HNSCC), according to preliminary results of an ongoing phase II proof-of-concept trial (NCT02383927).
Read More
Exciting Response Rates Seen in Updates Findings of bb2121 in Multiple Myeloma
December 13th 2017Chimeric antigen receptor T-cell therapy with bb2121 demonstrated an objective response rate of 94% in patients with relapsed/refractory multiple myeloma, according to findings from a dose-escalation study. The senior study author, James N. Kochenderfer, MD, presented updated findings from the study during the 2017 ASH Annual Meeting, and commented that 89% of patients had a very good partial response or better, and 56% of patients had a complete remission. <br />
Read More
Jennifer Eads, MD, assistant professor of medicine, senior clinical instructor of medicine, University Hospitals Cleveland Medical Center, discusses the difficulties in diagnosing G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), and the varying treatment approaches for these subsets of patients.
Watch
The Current Role of Checkpoint Inhibitors in Head and Neck Cancer
October 10th 2017Everett E. Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, Chair, Department of Medicine, discusses the current role of checkpoint inhibitors for the treatment of head and neck cancer during the ESMO 2017 Congress.
Watch
Teknos Chosen for Seidman Cancer Center
September 26th 2017Theodoros N. Teknos, MD, has been chosen as the new president and scientific officer of the University Hospitals Seidman Cancer Center. He will be taking over for the current president Nathan Levitan, MD, who will be retiring this year after 9 years in this position.
Read More
Supplemental BLA for New Nivolumab Dosing Schedule Accepted by FDA
July 27th 2017Supplemental Biologics License Applications (sBLAs) were sent to and accepted by the FDA for a new dosing schedule for nivolumab (Opdivo) across all of the agent's indications as a montherapy, according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor.
Read More
Ferris Named Director of UPMC Hillman Cancer Center
June 30th 2017Robert L. Ferris, MD, PhD, a renowned expert in immunotherapy and a specialist in head and neck cancer, has been named director of the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center. His new position will start July 1.
Read More
Searching for the Key to Immunotherapy Response in Head and Neck Cancer
April 18th 2017Immunotherapy agents have shown great promise for the treatment of patients with head and neck cancer; however, only a small subset of patients reap these benefits. Thus, the question becomes: which patients are more likely to benefit from these therapies, and why?
Read More
Adjusting Dosing to Increase Efficacy of Cetuximab in Head and Neck Cancer
April 10th 2017Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses how dosing adjustments may be used to increase the efficacy of agents, such as cetuximab (Erbitux) in patients with head and neck cancer.
Watch
EMA Recommends Nivolumab for Approval in Head and Neck Cancer
March 24th 2017Nivolumab (Opdivo) has been recommended for approval by EMA’s Committee for Medicinal Products for Human Use for the treatment of patients with squamous cell cancer of the head and neck following progression on platinum-based therapy.
Read More
Globetrotting Head and Neck Cancer Show Hits 8 Countries
March 22nd 2017The International Federation of Head and Neck Oncologic Societies recently completed its fourth tour, with 8 experts in the field of head and neck oncology traveling to 8 countries over a month to offer continuing medical education courses on treatment paradigms and surgical techniques in head and neck cancer across the world.
Read More
Immunotherapy Making Its Mark on Head and Neck Cancer
March 22nd 2017Following the approval of 2 immunotherapy agents, pembrolizumab and nivolumab for the treatment of patients with head and neck cancer over the last 6 months, immunotherapy is making its mark on the treatment paradigm for HNC.
Read More